Draximage will radiolabel some Med Discovery protein drugs to analyze effectiveness.
Med Discovery and Draximage are collaborating to explore the combination of the former’s targeted protein therapeutics with the latter’s radiopharmaceutical background in the therapeutic and diagnostics field.
Med Discovery reports that its preclinical candidates are potential therapeutic agents for prostate cancer as well as other cancers. This partnership provides initially for the radiolabeling of certain proteins to assess the enhancement of their action and their capability to detect microtumors.
The proteins will be produced at Med Discovery in Switzerland and radiolabeled by Draximage in Canada.
